// App-Quantinova.ai

473 : Mavrilimumab, a human monoclonal antibody targeting GM-CSFRα, inhibits polarization to myeloid-derived suppressor cells (MDSCs) that express PD-L1 and restores T-cell proliferation in vitro

Researchers

Presenter

  • Luis Carvajal

Principal Investigators

  • Luciana Gneo

  • Carmela De Santo

  • Matt Perez

  • Tracy Garron

  • Francis Mussai

  • Annalisa DAndrea

Medical Centers

  • Kiniksa Pharmaceuticals, Lexington, MA, USA

  • University of Birmingham, Birmingham, United Kingdom

Locations

  • United States

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Solid malignancies

Biomarkers

  • Cluster of Differentiation 2AP

  • Cluster of Differentiation 14

  • Cluster of Differentiation 206

  • Cluster of Differentiation 4

  • Programmed death-ligand 1

  • Cluster of differentiation 8A

  • Granulocyte-macrophage-colony stimulating factor

  • Interleukin-2

  • Human Leukocyte Antigen – DR isotype

Drug/Treatment

  • Mavrilimumab

  • GM-CSF

Outcome

  • N/A

Study Design

  • N/A

Phase

  • II

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved